TTM
−$0.35
YoY change
-35.1%
5Y CAGR
—
Peak year (2021)
$1.76
Latest annual
−$0.24
EPS (Diluted) history chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: −$0.24
EPS (Diluted) growth chart for Ovid Therapeutics (OVID) from 2014 to 2025
Latest: -35.1%
EPS (Diluted) history table for Ovid Therapeutics (OVID) from 2014 to 2025
| 2025 | −$0.24 | -35.1% | +$0.13 | ||
| 2024 | −$0.37 | -50.0% | +$0.37 | ||
| 2023 | −$0.74 | -3.9% | +$0.03 | ||
| 2022 | −$0.77 | -143.8% | −$2.53 | ||
| 2021 | $1.76 | -226.6% | +$3.15 | ||
| 2020 | −$1.39 | -7.9% | +$0.12 | ||
| 2019 | −$1.51 | -28.4% | +$0.60 | ||
| 2018 | −$2.11 | -37.0% | +$1.24 | ||
| 2017 | −$3.35 | +193.9% | −$2.21 | ||
| 2016 | −$1.14 | +70.1% | −$0.47 | ||
| 2015 | −$0.67 | +612.8% | −$0.58 | ||
| 2014 | −$0.09 | — | — |
- 2025−$0.24-35.1%
- 2024−$0.37-50.0%
- 2023−$0.74-3.9%
- 2022−$0.77-143.8%
- 2021$1.76-226.6%
- 2020−$1.39-7.9%
- 2019−$1.51-28.4%
- 2018−$2.11-37.0%
- 2017−$3.35+193.9%
- 2016−$1.14+70.1%
- 2015−$0.67+612.8%
- 2014−$0.09—
EPS (Diluted) values are taken from Ovid Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Ovid Therapeutics (OVID)
According to Ovid Therapeutics's latest reported financial statements, the company's current diluted EPS (TTM) is −$0.35. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Ovid Therapeutics (OVID) most recent annual diluted EPS stands at −$0.24 (2025) – plunged 35.1% year-over-year.
Ovid Therapeutics diluted EPS plunged from $1.76 in 2021 to −$0.24 in 2025, a 113.6% drawdown.
$1.76 stands as the all-time-high annual diluted EPS, posted in 2021, against a low of −$3.35 during 2017.
Ovid Therapeutics EPS (Diluted) by Year
Ovid Therapeutics EPS (Diluted) 2025: −$0.24
Ovid Therapeutics posted diluted EPS of −$0.24 in 2025, plunged 35.1% below 2024.
Ovid Therapeutics EPS (Diluted) 2024: −$0.37
In 2024, Ovid Therapeutics reported diluted EPS of −$0.37, plunged 50.0% below 2023.
Ovid Therapeutics EPS (Diluted) 2023: −$0.74
Ovid Therapeutics diluted EPS in 2023 was −$0.74, edged down 3.9% below 2022.
Ovid Therapeutics EPS (Diluted) 2022: −$0.77
2022's diluted EPS for Ovid Therapeutics came in at −$0.77, plunged 143.8% below 2021.
Ovid Therapeutics EPS (Diluted) 2021: $1.76
Ovid Therapeutics diluted EPS in 2021 was $1.76.
See more financial history for Ovid Therapeutics (OVID). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Ovid Therapeutics (OVID), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Ovid Therapeutics (OVID) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation